الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
This study was a case-control study that was carried out at Clinical Pathology Department, Assiut University Hospital and in the Cytogenetic laboratory, Clinical pathology Department, south Egypt cancer institute The study has included fifty newly diagnosed MM patients presented to Clinical Hematology Department at Assiut University Hospital and the South Egypt Cancer Institute from 2020 to 2023. Also, twenty age- and sex- matched controls (patients with non-malignant diseases, e.g. thrombocytopenia and hypoplasia) were included in this study. An informed written consent was taken from all cases. All MM patients were proven to have MM according to IMWG Criteria for MM and Related Plasma Cell Disorders The aim of the present work is to detect ZNF217 by FISH in newly diagnosed MM patients and evaluate ZNF217 in MM patients as a prognostic marker.I-Inclusion criteri 1. Newly diagnosed MM patientsprio an therapeutic Intervention, who fulfill the criteria of myeloma diagnosis 2. Either sex was eligible. 3. Age for study: 30 years or more.